XML 108 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue recognition (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Summary of Disaggregation of Revenue The Company's revenues disaggregated by the major sources were as follows:
Year Ended December 31,
2023
2022
2021
USGNon-USGTotalUSGNon-USGTotalUSGNon-USGTotal
Commercial Product sales$0.8 $496.5 $497.3 $0.8 $385.8 $386.6 $2.2 $435.8 $438.0 
MCM Product sales373.5 73.7 447.2 444.6 135.0 579.6 527.8 58.1 585.9 
Bioservices:
Services— 72.8 72.8 — 105.0 105.0 — 310.3 310.3 
Leases— 5.7 5.7 — 4.9 4.9 243.1 62.1 305.2 
Total Bioservices$— $78.5 $78.5 $— $109.9 $109.9 $243.1 $372.4 $615.5 
Contracts and grants20.4 5.9 26.3 37.2 4.2 41.4 130.2 4.0 134.2 
Total revenues$394.7 $654.6 $1,049.3 $482.6 $634.9 $1,117.5 $903.3 $870.3 $1,773.6 
Schedules of Concentration of Risk, by Risk Factor
For the years ended December 31, 2023, 2022 and 2021, the Company's product sales from NARCAN®, Other commercial products, Anthrax MCM, Smallpox MCM and Other products as a percentage of total product sales were as follows:
Year Ended December 31,
202320222021
% of product sales:   
Commercial Products:
NARCAN®
51 %39 %42 %
Other Commercial products1 %1 %— %
MCM Products:
Anthrax MCM20 %30 %26 %
Smallpox MCM18 %24 %26 %
Other Products10 %6 %6 %
Summary of Deferred Revenue Contract Liabilities The following table presents the roll forward of the contract liabilities:
 Contract Liabilities
Balance at December 31, 2022$31.7 
Balance at December 31, 2023$29.9 
Revenue recognized in the period from amounts included in contract liability at the beginning of the period:$20.2 
Schedule of Accounts Receivable, Net
The following table summarizes the components of "Accounts receivable, net" as presented on the Consolidated Balance Sheets:
 December 31,
20232022
Accounts receivable:
Billed$141.8 $102.7 
Unbilled51.4 57.2 
Allowance for expected credit losses(2.2)(0.7)
Accounts receivable, net$191.0 $159.2